Trials / Completed
CompletedNCT01878448
A Phase II Study of Anlotinib in STS Patients
Phase 2 Study of Anlotinib in Advanced Soft Tissue Sarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 166 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. ALTN is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2 and VEGFR3. It has the obvious resistance to new angiogenesis. The protocol is to explore ALTN for the effectiveness of advanced soft tissue sarcoma and security.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2015-10-01
- Completion
- 2017-04-30
- First posted
- 2013-06-17
- Last updated
- 2019-05-22
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01878448. Inclusion in this directory is not an endorsement.